Ajanta Pharma Limited
NSE: AJANTPHARM
Employs 10,421 permanent employees and workers, 8.2% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹1,102 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2022 | Standalone | 7,234 | — | 2,348 | — |
| 31 Mar 2023 | Standalone | 7,713 | 479(6.6%) | 2,557 | 209(8.9%) |
| 31 Mar 2024 | Group⚠ | 8,073 | 360(4.7%) | 2,295 | −262(10.3%) |
| 31 Mar 2025 | Group | 9,628 | 1,555(19.3%) | 2,609 | 314(13.7%) |
| 31 Mar 2026 | Group | 10,421 | 793(8.2%) | 2,785 | 176(6.8%) |
- ⚠The reporting scope changed from the previous period, so the two are not comparable.
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 1,102 | −27(2.4%) | 246 | 4(1.7%) | 252 | 17(7.2%) | |
| Quarter ended 30 Sept 2024 | 1,129 | 52(4.8%) | 242 | −24(9.0%) | 235 | −1(0.4%) | |
| Quarter ended 30 Jun 2024 | 1,077 | 151(16.3%) | 266 | 50(23.2%) | 236 | 73(44.8%) | |
| Quarter ended 31 Mar 2024 | 926 | −159(14.6%) | 216 | 0(0.0%) | 163 | −57(25.9%) | |
| Quarter ended 31 Dec 2023 | 1,085 | 140(14.8%) | 216 | 11(5.4%) | 220 | 8(3.8%) | |
| Quarter ended 30 Sept 2023 | 945 | −70(6.9%) | 205 | 9(4.6%) | 212 | 0(0.0%) | |
| Quarter ended 30 Jun 2023 | 1,015 | 166(19.6%) | 196 | −11(5.3%) | 212 | 95(81.2%) | |
| Quarter ended 31 Mar 2023 | 849 | −26(3.0%) | 207 | 31(17.6%) | 117 | −7(5.7%) | |
| Quarter ended 31 Dec 2022 | 875 | 109(14.2%) | 176 | 30(20.5%) | 124 | −11(8.2%) | ⚠ |
| Quarter ended 31 Mar 2022 | 766 | −43(5.3%) | 146 | −2(1.4%) | 135 | −60(30.8%) | ⚠ |
| Quarter ended 31 Dec 2021 | 809 | −15(1.8%) | 148 | 1(0.7%) | 195 | −2(1.0%) | ⚠ |
| Quarter ended 30 Sept 2021 | 824 | 81(10.9%) | 147 | 2(1.4%) | 197 | 4(2.1%) | ⚠ |
| Quarter ended 30 Jun 2021 | 743 | −5(0.7%) | 145 | 12(9.0%) | 193 | 38(24.5%) | ⚠ |
| Quarter ended 31 Mar 2021 | 748 | 15(2.1%) | 133 | 10(8.1%) | 155 | −25(13.9%) | ⚠ |
| Quarter ended 31 Dec 2020 | 733 | 56(8.3%) | 123 | 5(4.2%) | 180 | −45(20.0%) | ⚠ |
| Quarter ended 30 Sept 2020 | 677 | 116(20.7%) | 118 | −6(4.8%) | 225 | 109(94.0%) | ⚠ |
| Quarter ended 30 Jun 2020 | 561 | 0(0.0%) | 124 | 7(6.0%) | 116 | 27(30.3%) | ⚠ |
| Quarter ended 31 Mar 2020 | 561 | 30(5.7%) | 117 | 10(9.3%) | 89 | −19(17.6%) | ⚠ |
| Quarter ended 31 Dec 2019 | 531 | −28(5.0%) | 107 | 1(0.9%) | 108 | −13(10.7%) | ⚠ |
| Quarter ended 30 Sept 2019 | 559 | 13(2.4%) | 106 | −1(0.9%) | 121 | −3(2.4%) | ⚠ |
| Quarter ended 30 Jun 2019 | 546 | 132(31.9%) | 107 | 10(10.3%) | 124 | 83(202.4%) | ⚠ |
| Quarter ended 31 Mar 2019 | 414 | −38(8.4%) | 97 | −3(3.0%) | 41 | −54(56.8%) | ⚠ |
| Quarter ended 31 Dec 2018 | 452 | −13(2.8%) | 100 | 3(3.1%) | 95 | −9(8.6%) | ⚠ |
| Quarter ended 30 Sept 2018 | 465 | 2(0.4%) | 97 | 0(0.0%) | 104 | 26(33.3%) | ⚠ |
| Quarter ended 31 Mar 2018 | 463 | — | 97 | — | 78 | — | ⚠ |